Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 -2.54%83 Current Ratio is 2.75 as of Mar. 2026, which is 20% above its 10-year median of 2.30. GuruFocus rates SHSE:688656 with a GF Score™ of 83/100 and a GF Value™ of ¥89.27 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 853 Medical Devices & Instruments companies, HOB Biotech Group ranks better than 54.51% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. HOB Biotech Group's current ratio for the quarter that ended in Mar. 2026 was 2.75.
HOB Biotech Group has a current ratio of 2.75. It generally indicates good short-term financial strength.
The historical rank and industry rank for HOB Biotech Group's Current Ratio or its related term are showing as below:
SHSE:688656'
s Current Ratio Range Over the Past 10 Years
Min: 0.96 Med: 2.3 Max: 11.53
Current: 2.75
During the past 10 years, HOB Biotech Group's highest Current Ratio was 11.53. The lowest was 0.96. And the median was 2.30.
SHSE:688656's Current Ratio is ranked better than 54.51% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs SHSE:688656: 2.75
HOB Biotech Group (SHSE:688656) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
HOB Biotech Group Current Ratio Related Terms
HOB Biotech Group Current Ratio Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, HOB Biotech Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group (SHSE:688656) has a Current Ratio of 2.75 as of Mar. 2026. This is 20% above median its historical median of 2.30. Over the past decade, HOB Biotech Group's Current Ratio has ranged from 0.96 to 11.53. According to the industry distribution chart, HOB Biotech Group ranks #388 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 45.5%.
Is HOB Biotech Group's Current Ratio too high?
HOB Biotech Group's current Current Ratio of 2.75 is 20% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 11.53. The Medical Devices & Instruments industry median Current Ratio is 2.49. HOB Biotech Group's value of 2.75 is 10.4% above this industry median. Based on the distribution chart, HOB Biotech Group ranks #388 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, HOB Biotech Group has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #388 out of 853 companies for Current Ratio. This puts HOB Biotech Group in the upper half of its industry. The industry median Current Ratio is 2.49. HOB Biotech Group's value of 2.75 is 10.4% above this benchmark. Historically, HOB Biotech Group's own Current Ratio has ranged from 0.96 to 11.53 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 2.49, HOB Biotech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Current Ratio of 2.75 is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Current Ratio is 2.75, which is 20% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥89.27, compared to a current price of ¥79.20 — trading 11.3% below its estimated fair value. The current Current Ratio is 2.75, which is 20% above median its 10-year median of 2.30 and 10.4% above the Medical Devices & Instruments industry median of 2.49. HOB Biotech Group's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Current Ratio is 2.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥79.20 is trading 11.3% below its estimated GF Value™ of ¥89.27.
GuruFocus considers HOB Biotech Group to be Modestly Undervalued.
Key valuation signals for SHSE:688656:
Current Ratio: 2.75 (20% above median its 10-year median of 2.30)
GF Value™: ¥89.27 vs. price of ¥79.20 (11.3% below fair value)
Industry Position: 10.4% above the Medical Devices & Instruments median (#388 of 853)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
83GF Score
Get the complete analysis for SHSE:688656
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
